P1.03Analysis of Biomarkers and PK Modeling of ABT-767 in Patients With BRCA1/BRCA2-Mutated Tumors or High Grade Serous Ovarian Cancer.

De Jonge M, Van Herpen C,J Gietema,K Timms,M Dunbar, R Hetman, C Serpenti, Hui Xiong,Meifang Zhu,R K Mittapalli,Peter Ansell,S Shepherd

Annals of Oncology（2015）

引用 1|浏览20

暂无评分

摘要

Background: Malignancies with homologous repair deficiency (HRD) are more dependent on PARP for DNA repair than normal cells. This trial assessed safety and PK of the oral PARP-1 and -2 inhibitor, ABT-767. Here we present biomarker and PK modeling results in patients (pts) with high-grade serous ovarian, fallopian tube, or primary peritoneal cancer or solid tumors with germline (g) BRCA1 or BRCA2 mutation.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要